Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway

Cancer Science

Volumn 97, Issue 5, 2006, Pages 430-436

  Park, Hae Young ^a   Kim, Min Kyoung ^a   Moon, Sang Ik ^a   Cho, Youl Hee ^a   Lee, Chul Hoon ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; MCS C 2; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GENE ACTIVATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SERINE; SIGNAL TRANSDUCTION; TOYOCAMYCIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33645545037     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00195.x     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969; 23: 24-34.
3. Abbas F, Scardino PT. The natural history of clinical prostate carcinoma. Cancer 1997; 80: 827-33.
4. Effert PJ, McCoy RH, Walther PJ, Liu ET. P53 gene alterations in human prostate carcinoma. J Urol 1993; 150: 257-61.
5. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
6. Lim H, Kim MK, Cho YH, Kim JM, Lim Y, Lee CH. Inhibition of cell cycle progression and induction of apoptosis in HeLa cells by HY558-1, a novel CDK inhibitor isolated from Penicillium minioluteum F558. J Microbiol Biotechnol 2004; 14: 978-84.
7. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998; 12: 2973-83.
8. Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 2000; 462: 179-88.
9. Park SG, Cheon JY, Lee YH et al. A specific inhibitor of cyclin-dependent protein kinase, CDC2 and CDK2. Mol Cells 1996; 6: 679-83.
10. Aszalos A, Lemanski P, Robison R, Davis S, Berk B. Identification of antibiotic 1037 as toyocamycin. J Antibiot (Tokyo) 1966; 19: 285.
11. Sverak L, Bonar RA, Langlois AJ, Beard JW. Inhibition by toyocamycin of RNA synthesis in mammalian cells and in normal and avian tumor virus-infected chick embryo cells. Biochim Biophys Acta 1970; 224: 441-50.
12. Wilson WL. Phase I study with toyocamycin (NSC-63701). Cancer Chemother Report 1968; 52: 301-3.
13. Clercq EJ, Balzarini D, Madej F, Hansske Robins MJ. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J Med Chem 1987; 30: 481-6.
14. Finch RA, Revankar GR, Chan PK. Structural and functional relationships of toyocamycin on NPM-translocation. Anticancer Drug Des 1997; 12: 205-15.
15. Gupta PK, Nassiri MR, Coleman LA, Wotring LL, Drach JC, Townsend LB. Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. J Med Chem 1989; 32: 402-8.
16. Krawczyk SH, Nassiri MR, Kucera LS et al. Synthesis and antiproliferative and antiviral activity of 2′-deoxy-2′-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. J Med Chem 1995; 38: 4106-14.
17. Kim MK, Cho YH, Kim JM et al. Inhibition of cell cycle progression in human promyelocytic leukemia HL-60 cells by MCS-C2, novel cyclin-dependent kinase inhibitor. J Microbiol Biotechnol 2003; 13: 607-12.
18. Kim MK, Cho YH, Kim JM et al. Induction of apoptosis in human leukemia cells by MCS-C2 via caspase-dependent Bid cleavage and cytochrome c release. Cancer Lett 2005; 223: 239-47.
19. -ΔΔCT method. Methods 2001; 25: 402-8.
20. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 1989; 49: 5870-8.
21. Hickmann JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-39.
22. Tewari M, Quan LT, O'Rourke K et al. Yama/CPP3β, a mammalian homolog of CED-3 is a crmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81: 801-9.
23. Verhagen AM, Ekert PG, Pakusch M et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
24. Fiscella M, Ullrich SJ, Zambrano N et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 1993; 8: 1519-28.
25. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289-300.
26. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-34.
27. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
28. Kohn KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 1999; 10: 2703-34.
29. Puri PL, Maclachlan TK, Levrero M, Giordano A. The intrinsic cell cycle: from yeast to mammals. In: Stein GS, Baserga R, Giordano A, Denhardt DT, eds. The Molecular Basis of Cell Cycle and Growth Control. New York: Wiley, 1999; 15-79.
30. Kundsen ES, Wang JY. Dual mechanism for the inhibition of E2F binding to Rb by cyclin-dependent kinase-mediated Rb phosphorylation. Mol Cell Biol 1997; 17: 5771-83.
31. Lim HY, Kim MK, Cho YH, Kim JM, Lim YH, Lee CH. Inhibition of cell cycle progression and induction of apoptosis in HeLa cells by HY558-1, a novel CDK inhibitor isolated from Penicillium minioluteum F558. J Microbiol Biotechnol 2004; 14: 978-84.
32. Lee CH, Lim HY, Kim MK et al. Isolation and biological properties of novel cell cycle inhibitor, HY558, isolated from Penicillium minioluteum F558. J Microbiol Biotechnol 2002; 12: 470-5.
33. Sedlak TW, Oltvai ZN, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-8.